Profile data is unavailable for this security.
About the company
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
- Revenue in USD (TTM)0.00
- Net income in USD-13.50m
- Incorporated2021
- Employees--
- LocationEstrella Immunopharma Inc5858 Horton St, Suite 370EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 318-9098
- Fax+1 (847) 827-5303
- Websitehttps://www.estrellabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 49.98m | 21.00 | -- | 7.06 | -- | 9.51 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Impact Biomedical Inc | 25.00k | -44.19m | 50.22m | 2.00 | -- | -- | -- | 2,008.73 | -3.76 | -3.76 | 0.0021 | -0.9691 | 0.0008 | -- | 3.33 | 12,500.00 | -136.32 | -18.99 | -260.12 | -26.29 | 52.00 | -- | -176,952.00 | -78,189.58 | 0.0182 | -0.2682 | 1.63 | -- | -- | -- | -469.83 | -- | -- | -- |
| Cingulate Inc | 0.00 | -22.06m | 50.60m | 13.00 | -- | 11.31 | -- | -- | -5.35 | -5.35 | 0.00 | 0.5811 | 0.00 | -- | -- | 0.00 | -183.12 | -157.80 | -264.65 | -303.36 | -- | -- | -- | -- | -- | -19.54 | 0.4783 | -- | -- | -- | 33.95 | -- | -26.92 | -- |
| NRX Pharmaceuticals Inc | 242.00k | -38.06m | 51.14m | 2.00 | -- | -- | -- | 211.31 | -2.32 | -2.32 | 0.0141 | -0.9304 | 0.0249 | -- | -- | -- | -391.21 | -210.73 | -- | -603.16 | 59.92 | -- | -15,727.69 | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 51.34m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 51.87m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -75.08m | 52.70m | 14.00 | -- | 0.4376 | -- | -- | -11.39 | -11.39 | 0.00 | 17.76 | 0.00 | -- | -- | 0.00 | -31.00 | -34.59 | -32.06 | -36.59 | -- | -- | -- | -469,515.20 | -- | -19.23 | 0.4127 | -- | -- | -- | 52.50 | -- | 116.55 | -- |
| Estrella Immunopharma Inc | 0.00 | -13.50m | 54.64m | -- | -- | -- | -- | -- | -0.3697 | -0.3697 | 0.00 | -0.2605 | 0.00 | -- | -- | -- | -371.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Tscan Therapeutics Inc | 8.42m | -142.60m | 55.18m | 146.00 | -- | 0.3832 | -- | 6.55 | -1.12 | -1.12 | 0.066 | 2.54 | 0.0276 | -- | -- | 43,417.53 | -46.73 | -38.91 | -51.63 | -43.93 | -- | -- | -1,692.96 | -735.59 | -- | -- | 0.1837 | -- | -86.62 | -- | -42.91 | -- | 25.13 | -- |
| Grace Therapeutics, Inc | 0.00 | -7.82m | 55.55m | 32.00 | -- | 0.8074 | -- | -- | -0.5851 | -0.5851 | 0.00 | 4.45 | 0.00 | -- | -- | -- | -11.85 | -24.13 | -12.22 | -25.07 | -- | -- | -- | -48,136.22 | -- | -- | 0.00 | -- | -- | -- | 25.56 | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 81.24k | -14.75m | 56.45m | 12.00 | -- | -- | -- | 694.91 | -12.37 | -12.37 | 0.0566 | -3.65 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Metagenomi Therapeutics Inc | 30.91m | -88.74m | 57.05m | 124.00 | -- | 0.3198 | -- | 1.85 | -2.39 | -2.39 | 0.8308 | 4.75 | 0.102 | -- | 39.91 | 153,034.70 | -29.27 | -- | -33.42 | -- | -- | -- | -287.06 | -- | -- | -- | 0.00 | -- | 16.84 | -- | -14.36 | -- | -- | -- |
| Beyondspring Inc | 0.00 | -7.83m | 59.53m | 40.00 | -- | -- | -- | -- | -0.1942 | -0.0148 | 0.00 | -0.788 | -- | -- | -- | 0.00 | -- | -61.84 | -- | -81.30 | -- | -- | -- | -6,633.90 | -- | -- | -- | -- | -- | -- | 35.26 | -- | 123.69 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.67m | 59.54m | 0.00 | -- | -- | -- | -- | -0.1455 | -0.1455 | 0.00 | -0.1168 | 0.00 | -- | -- | -- | -5,576.42 | -14,417.91 | -- | -- | -- | -- | -- | -- | -- | -684.26 | -- | -- | -- | -- | -106.65 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Estrella Immunopharma Inc's reporting currency: US Dollar USD
1.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 382.47k | 1.01% |
| Geode Capital Management LLCas of 30 Sep 2025 | 101.49k | 0.27% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 66.30k | 0.18% |
| Citadel Securities LLCas of 30 Sep 2025 | 50.12k | 0.13% |
| ATW SPAC Management LLCas of 30 Sep 2025 | 40.00k | 0.11% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 22.35k | 0.06% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 21.71k | 0.06% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 10.69k | 0.03% |
| XTX Markets LLCas of 30 Sep 2025 | 10.37k | 0.03% |
| Maso Capital Partners Ltd.as of 30 Sep 2025 | 10.00k | 0.03% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
